Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe IBD
NCT04919252Phase 3Unknown
- Sponsor
- Yonsei University
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, ulcerative colitis (UC), sponsored by Yonsei University. Status: unknown.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04919252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919252.